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Evidence of current and past Middle East respiratory 
syndrome coronavirus (MERS-CoV) infection in drome-
dary camels slaughtered at an abattoir in Kano, Nigeria 
in January 2015, was sought by reverse transcription-
quantitative polymerase chain reaction (RT-qPCR) and 
serology. MERS-CoV RNA was detected in 14 (11%) 
of 132 nasal swabs and antibody in 126 (96%) of 131 
serum samples. Phylogenetic analyses demonstrate 
that the viruses in Nigeria are genetically distinct from 
those reported in the Arabian peninsula.
Introduction
Middle East respiratory syndrome coronavirus (MERS-
CoV) is a novel lineage C betacoronavirus that can 
cause an acute viral respiratory disease in humans. 
As of 13 November 2015, there were 1,618 laboratory-
confirmed cases of MERS reported to the World Health 
Organization (WHO), associated with 579 deaths 
[1,2]. Human disease is zoonotic in origin, although 
clusters of human-to-human transmission have been 
reported, especially within healthcare or family set-
tings [1]. Dromedary camels in the Middle East have a 
high seroprevalence for MERS-CoV and MERS-CoV RNA 
has been consistently detected in these animals, espe-
cially in settings such as camel abattoirs, where cam-
els from multiple origins are assembled. Camels are 
thus identified as a potential source of zoonotic MERS 
[3-6]. More than 60% of the global population of drom-
edary camels is distributed in African countries. Some 
of these countries are important camel exporters to 
the Arabian Peninsula [7]. MERS-CoV antibodies were 
also found with high prevalence in dromedary camels 
in these African countries with positive rates higher 
than 80% for the animals in Egypt, Ethiopia, Nigeria 
and Sudan, and of 30 to 54% in Tunisia [8]. However, 
zoonotic human disease has so far been reported only 
from countries in the Middle-East. The reason for the 
absence of zoonotic disease in Africa is unclear.
The genetic diversity of the virus in Africa is poorly 
defined. The only reports of genetic sequences from 
Africa have been those from viruses in Egypt and these 
were genetically distinct from those currently causing 
human disease in the Middle East [6]. However, phe-
notypic characterisation of these viruses revealed they 
have capacity to infect tissues of the human respira-
tory tract [9]. There is a need to better understand the 
ecology of MERS-CoV within Africa and the viral genetic 
diversity within this region. We report detection rates 
of MERS-CoV in dromedary camels in the abattoir in 
Kano, Nigeria, where around 55 camels are slaughtered 
per day, making it the largest camel abattoir in that 
country. Viral sequences derived from nasal swabs of 
these animals are also phylogenetically analysed.
Methods
The study was carried out on seven consecutive days 
in January 2015. Nasal swabs and blood were collected 
from camels shortly after slaughter at the abattoir in 
Kano, Nigeria. Some of the animals slaughtered at this 
abattoir originate from northern Nigeria, as well as 
neighbouring African countries including Chad, Libya, 
Mali, Niger and Sudan. Nasal swabs were collected 
in RNALater (Ambion) or in virus transport medium 
and stored at -80 °C. Blood samples were collected 
and serum separated. The age of the sampled camels 
was assessed by dental examination. Samples were 
shipped to the laboratory at The University of Hong 
Kong on dry ice for laboratory investigation.
Total nucleic acid was extracted from swab samples 
using EasyMag (Biomerieux), and tested for the pres-
ence of MERS-CoV RNA by upstream of the Envelope 
gene (UpE) reverse transcription-quantitative poly-
merase chain reaction (RT-qPCR) hydrolysis probe 
assay. All positive specimens were confirmed by a sec-
ond RT-qPCR assay targeting the open reading frame 
(ORF)1a region of the genome [6]. The S2 region of 
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the positive samples were amplified and sequenced 
for phylogenetic characterisation [10]. The full spike 
gene and 5kb of the ORF1b region of one virus were 
sequenced for more detailed analysis.
Sera were screened at a dilution of 1:20 for the detec-
tion of MERS-CoV antibody using a validated MERS-
spike pseudoparticle neutralisation test (ppNT) as 
previously described [5].
Results
Overall, 132 of the 385 animals slaughtered during 
this period (34%; daily range: 24%–43%) were sam-
pled shortly after slaughter. Nasal swabs were col-
lected from all 132 camels, while serum samples were 
obtained from 131.
MERS-CoV RNA was detected by both UpE and ORF-1a 
RT-qPCR assays in 14 (11%), nasal swabs with positive 
samples being found in five of the seven days sampled 
(Table). Threshold cycles of the positives by UpE assay 
ranged from 23.8 to 37.4, which represented 3.54x102 
to 2.60x106 copies of virus RNA per 1 mL of original 
swab sample. Ages of the MERS-CoV positive animals 
ranged from three to 12 years-old.
On a daily basis, the seroprevalence ranged from 82% 
to 100%, giving an overall seroprevalence of 95% 
(Table). All 14 animals positive by RT-qPCR were also 
positive for MERS-CoV antibody by ppNT. The highest 
MERS-CoV RNA positive rate by RT-qPCR was detected 
on the days with lowest seroprevalence.
We sequenced a 600 bp region in S2 gene of six 
selected RT-qPCR positive samples, representing at 
Figure 1
Phylogenetic analysis of the Middle East respiratory syndrome coronaviruses (MERS-CoVs) recovered from Nigeria 
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mid-point rooted. Sequences generated from this study are in bold with GenBank accession numbers: KU201953–58. Accession numbers of 
other sequences retrieved from GenBank are shown in brackets.
3www.eurosurveillance.org
Vi
ru
s 
cl
ad
e 
Nigeria-HKU004 
Nigeria-HKU006 
Nigeria-HKU012 
Nigeria-HKU061 
Nigeria-HKU079 
Nigeria-HKU107 
NRCE-HKU205 
NRCE-HKU270 
HCoV_2c_EMC 
Jordan-N3/2012 
Abu_Dhabi_UAE_9 
Florida/USA2 
England_1 
KFU-HKU_1 
Hafr-Al-Batin_1 
Riyadh_4 
FRA/UAE 
KOR/KNIH/002 
Hu/Riyadh-2049 
Hu/Riyadh-2466 
ChinaGD 
Ni
ge
ria
-H
KU
00
4 
Un
de
fin
ed
 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni
ge
ria
-H
KU
00
6 
Un
de
fin
ed
 
1 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni
ge
ria
-H
KU
01
2 
Un
de
fin
ed
 
1 
1 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni
ge
ria
-H
KU
06
1 
Un
de
fin
ed
 
0.
99
3 
0.
99
3 
0.
99
3 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni
ge
ria
-H
KU
07
9 
Un
de
fin
ed
 
1 
1 
1 
0.
99
3 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni
ge
ria
-H
KU
10
7 
Un
de
fin
ed
 
1 
1 
1 
0.
99
3 
1 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eg
yp
t N
RC
E-H
KU
20
5 
Un
de
fin
ed
 
0.
98
6 
0.
98
6 
0.
98
6 
0.
98
9 
0.
98
6 
0.
98
6 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eg
yp
t N
RC
E-H
KU
27
0 
Un
de
fin
ed
 
0.
99
3 
0.
99
3 
0.
99
3 
0.
99
6 
0.
99
3 
0.
99
3 
0.
99
3 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hu
m
an
_C
oV
_2
c_
EM
C 
A 
0.
99
1 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
8 
ID
 
 
 
 
 
 
 
 
 
 
 
 
 
Jo
rd
an
-N
3/
20
12
 
A 
0.
99
1 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
8 
1 
ID
 
 
 
 
 
 
 
 
 
 
 
 
Ab
u_
Dh
ab
i_
UA
E_
9 
B 
0.
98
6 
0.
98
6 
0.
98
6 
0.
98
9 
0.
98
6 
0.
98
6 
0.
98
9 
0.
99
3 
0.
99
4 
0.
99
4 
ID
 
 
 
 
 
 
 
 
 
 
 
Fl
or
id
a/
US
A2
_S
au
di
_A
ra
bi
a 
B 
0.
98
6 
0.
98
6 
0.
98
6 
0.
98
9 
0.
98
6 
0.
98
6 
0.
98
9 
0.
99
3 
0.
99
4 
0.
99
4 
0.
98
9 
ID
 
 
 
 
 
 
 
 
 
 
En
gl
an
d_
1 
B 
0.
98
9 
0.
98
9 
0.
98
9 
0.
99
3 
0.
98
9 
0.
98
9 
0.
99
3 
0.
99
6 
0.
99
8 
0.
99
8 
0.
99
3 
0.
99
6 
ID
 
 
 
 
 
 
 
 
 
KF
U-
HK
U_
1 
B 
0.
98
6 
0.
98
6 
0.
98
6 
0.
98
9 
0.
98
6 
0.
98
6 
0.
98
9 
0.
99
3 
0.
99
4 
0.
99
4 
1 
0.
98
9 
0.
99
3 
ID
 
 
 
 
 
 
 
 
Ha
fr-
Al
-B
at
in
_1
 
B 
0.
98
8 
0.
98
8 
0.
98
8 
0.
99
1 
0.
98
8 
0.
98
8 
0.
99
1 
0.
99
4 
0.
99
6 
0.
99
6 
0.
99
8 
0.
99
1 
0.
99
4 
0.
99
8 
ID
 
 
 
 
 
 
 
Ri
ya
dh
_4
 
B 
0.
98
9 
0.
98
9 
0.
98
9 
0.
99
3 
0.
98
9 
0.
98
9 
0.
99
3 
0.
99
6 
0.
99
8 
0.
99
8 
0.
99
3 
0.
99
6 
1 
0.
99
3 
0.
99
4 
ID
 
 
 
 
 
 
FR
A/
UA
E 
B 
0.
98
9 
0.
98
9 
0.
98
9 
0.
98
9 
0.
98
9 
0.
98
9 
0.
98
9 
0.
99
3 
0.
99
4 
0.
99
4 
0.
99
6 
0.
98
9 
0.
99
3 
0.
99
6 
0.
99
8 
0.
99
3 
ID
 
 
 
 
 
KO
R/
KN
IH
/0
02
 
B 
0.
98
4 
0.
98
4 
0.
98
4 
0.
98
8 
0.
98
4 
0.
98
4 
0.
98
8 
0.
99
1 
0.
99
3 
0.
99
3 
0.
99
4 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
6 
0.
99
1 
0.
99
4 
ID
 
 
 
 
Hu
/R
iy
ad
h-K
SA
-2
04
9 
B 
0.
98
8 
0.
98
8 
0.
98
8 
0.
99
1 
0.
98
8 
0.
98
8 
0.
99
1 
0.
99
4 
0.
99
6 
0.
99
6 
0.
99
1 
0.
99
8 
0.
99
8 
0.
99
1 
0.
99
3 
0.
99
8 
0.
99
1 
0.
99
3 
ID
 
 
 
Hu
/R
iy
ad
h-K
SA
-2
46
6 
B 
0.
98
6 
0.
98
6 
0.
98
6 
0.
98
9 
0.
98
6 
0.
98
6 
0.
98
9 
0.
99
3 
0.
99
4 
0.
99
4 
0.
98
9 
0.
99
6 
0.
99
6 
0.
98
9 
0.
99
1 
0.
99
6 
0.
98
9 
0.
99
1 
0.
99
8 
ID
 
 
Ch
in
aG
D 
B 
0.
98
4 
0.
98
4 
0.
98
4 
0.
98
8 
0.
98
4 
0.
98
4 
0.
98
8 
0.
99
1 
0.
99
3 
0.
99
3 
0.
99
4 
0.
99
1 
0.
99
1 
0.
99
4 
0.
99
6 
0.
99
1 
0.
99
4 
1 
0.
99
3 
0.
99
1 
ID
 
Fi
gu
re
 2
Pa
ir
w
ise
 si
m
ila
rit
ie
s b
et
w
ee
n 
nu
cl
eo
tid
e 
se
qu
en
ce
s o
f s
pi
ke
 S
2 
re
gi
on
 o
f M
id
dl
e 
Ea
st
 re
sp
ira
to
ry
 sy
nd
ro
m
e 
co
ro
na
vi
ru
se
s, 
in
clu
di
ng
 se
ve
ra
l r
ec
ov
er
ed
 fr
om
 N
ig
er
ia
 a
nd
 o
th
er
 
re
pr
es
en
ta
tiv
e 
vi
ru
se
s
ID
: i
de
nt
ic
al
 v
iru
s.
4 www.eurosurveillance.org
least one positive sample from each day with PCR-
positive samples. Phylogenetic analysis showed that 
these six viruses formed two distinct lineages, the 
virus from a camel sampled on 16 January being dis-
tinct from the others (Figure 1). 
Both of the Nigerian virus groups were distinct from 
previously known virus lineages. The Nigerian camel 
viruses were most closely related to virus NRCE-
HKU270 previously found in Egypt with nt sequence 
similarity of 99.3 to 99.6%. MERS-CoV in Nigeria were 
genetically distinct from viruses found in camels in the 
Middle East and viruses detected in humans in more 
recent years (nt sequence similarity ranging from 98.4 
to 99.4%) (Figure 2). 
The time-resolved phylogeny of the ORF1b region of 
one virus confirms these overall findings (Figure 3). 
We derived the nt sequence of the full spike gene of 
one virus Nigeria HKU004 and the deduced amino acid 
sequence is aligned and compared to those of other 
human and animal MERS-CoV in Figure 4. This reveals 
that the receptor binding domain, which is crucial 
for virus host range and tropism, is fully conserved. 
There are only two amino acid residues not previously 
reported in other MERS-CoV spike proteins; these being 
S 656 T and L 1200 F.
Discussion
We report high MERS-CoV seroprevalence in camels 
gathered in an abattoir in Nigeria with relatively high 
detection rates of virus in nasal swabs. Phylogenetic 
analysis revealed that these viruses are genetically dis-
tinct from viruses reported from camels or humans in 
the Arabia peninsula and cluster with, but are clearly 
distinct from those reported from Egypt. However, it is 
Figure 3
Time resolved phylogenetic tree of open reading frame (ORF)1b of Middle East respiratory syndrome coronaviruses (MERS-
CoVs) recovered in Africa and the Middle East, 2012–2015
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The time resolved phylogenetic tree was constructed using Bayesian evolutionary analysis by sampling trees (BEAST) with an uncorrelated 
lognormal relaxed clock based on open reading frame (ORF)1b (5,347 bp) gene sequences of representative MERS-CoVs. Median ages of 
the nodes with respective to MERS-CoV ChinaGD (the latest virus included) are shown. The tree is rooted to bat coronavirus Neoromicia. 
The sequence generated from this study (Nigeria-HKU004) is in bold and has GenBank accession number KU201959. GenBank accession 
numbers of other sequences retrieved for the phylogenetic analysis are shown in brackets.
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important to note that these Nigerian viruses remain 
genetically closely related to other MERS-CoV with 
an overall nt similarity of > 0.98 for the S2 gene. Thus 
these are almost certainly pertaining to one viral spe-
cies, and very likely (though not directly studied in the 
present work) also form one serotype. 
Although the animals in this study were sampled in 
Kano, Nigeria, some animals originated from neigh-
bouring African countries. The camels are kept within 
the abattoir for a number of days before slaughter 
allowing opportunity for virus cross-infection and 
amplification. Thus the viruses detected in this study 
may reflect viruses circulating in this wider region.
A limitation of this study is the short period within 
which the sampling was carried out. Thus it is unclear 
whether the high rate of virus detection reflects an all 
year-round pattern or if there are seasonal differences 
in virus activity. It has been suspected that virus activ-
ity in camels may increase during the calving season. 
In Nigeria, as in the Arabian peninsula, camel calving 
peaks during the January to March period. Thus it is 
possible that the rate of virus detection observed in 
this study reflects a seasonal peak. Indeed this was 
the rationale for targeting sampling within this time 
frame. Even if the observations of this study reflect a 
seasonal peak, the detection of MERS-CoV in camels 
slaughtered on five of seven days sampled, suggests 
intense exposure of humans to virus infected camels, 
whether seasonally or year round, and thus potentially 
a significant zoonotic threat.
It is not known if the MERS-CoV in Nigeria has similar 
zoonotic potential to viruses currently circulating in the 
Arabian peninsula. Other explanations for the lack of 
zoonotic MERS in Africa include differences in patterns 
of exposure to infected animals or animal products 
or differences in human susceptibility to MERS-CoV. 
Alternatively, MERS may indeed be occurring but 
unrecognised in Africa due to lack of awareness or 
diagnostic testing.
A second limitation of this study is that there were no 
virus isolates available for phenotypic characterisa-
tion and full genome sequence data were not available 
for genetic comparison across the whole genome with 
viruses known to infect humans. Comparison of the 
sequence of the spike gene with other MERS-CoV sug-
gests that the virus isolated in Nigeria appears to have 
competence to bind the dipeptidyl peptidase (DPP)-4 
receptor. Viruses isolated from Egypt, though geneti-
cally distinct, had comparable tropism and replication 
competence in ex vivo cultures of the human bronchus 
and lung to those viruses isolated from humans in Saudi 
Arabia [9]. Thus zoonotic potential of these viruses 
cannot be excluded. Further studies to determine the 
genetic diversity and biological characterisation of 
MERS-CoV across Africa are urgently needed. Studies 
looking into seroprevalence of humans exposed to set-
tings associated with such high levels of exposure to 
MERS-CoV such as camel abattoirs across Africa are 
also important to assess the extent of zoonotic spill-
over, if any.
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